Results 121 to 130 of about 27,986 (275)

Elevational variation in heart mass and suppression of hypoxia‐induced right ventricle hypertrophy in Andean leaf‐eared mice (Phyllotis)

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend In lowland mammals that ascend to high elevation, hypoxia‐induced changes in the pulmonary circulation can give rise to hypoxic pulmonary hypertension (HPH) and associated right‐ventricle (RV) hypertrophy. Andean mice with broad elevational ranges have greater heart mass relative to body size at higher elevations, but they ...
Naim M. Bautista   +9 more
wiley   +1 more source

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies.
Silvia Marchianò   +18 more
wiley   +1 more source

Hypertrophic obstructive cardiomyopathy [PDF]

open access: yesThe Journal of Thoracic and Cardiovascular Surgery, 1997
Morton E. Tavel   +2 more
openaire   +2 more sources

Myofibrillar Ca2+ sensitivity is uncoupled from troponin I phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin T [PDF]

open access: bronze, 2012
Christopher R. Bayliss   +10 more
openalex   +1 more source

The HRAS Variant c.175G>A (p.Ala59Thr) Causes a Predominantly Ectodermal Phenotype Lacking Classic Costello Syndrome Features

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 2, Page 407-418, February 2026.
ABSTRACT Costello syndrome (CS) is a rare dominant HRAS RASopathy characterized by curly hair, cardiac abnormalities, craniofacial anomalies, and developmental delay. HRAS codon 58, 59, and 60 variants are associated with milder phenotypes. We describe a three‐generation family with a previously unreported heterozygous HRAS variant c.175G>A (p.Ala59Thr)
Nikole Rautiainen   +10 more
wiley   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo   +22 more
wiley   +1 more source

Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement [PDF]

open access: yes, 2016
AIMS: Prevalence and clinical significance of right atrial enlargement (RAE) has been poorly characterized in hypertrophic cardiomyopathy. METHODS: One hundred and sixty consecutive patients with hypertrophic cardiomyopathy (35.5 ± 20 years; 64% men ...
Bossone, E   +11 more
core  

Home - About - Disclaimer - Privacy